We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s anti-parasitic drug Stromectol (ivermectin) is being studied in multiple clinical trials as a potential COVID-19 treatment, but — at least for now — the company is warning against its use. Read More
The AstraZeneca (AZ)/Oxford University COVID-19 vaccine remains effective against the fast-spreading UK viral variant, Oxford researchers have shown in a late-stage trial. Read More
Trials evaluating the effectiveness of a combined regimen of the Gamaleya Research Institute’s Sputnik V vaccine and the AstraZeneca/University of Oxford vaccine are set to begin next week in Azerbaijan, the United Arab Emirates and other Middle Eastern nations. Read More
UK researchers launched a new study yesterday to assess a combined COVID-19 vaccination regimen in older adults that includes the Pfizer/BioNTech and the AstraZeneca (AZ)/Oxford University vaccines. Read More
Johnson & Johnson (J&J) filed yesterday for FDA Emergency Use Authorization (EUA) of its single-dose COVID-19 vaccine — which if granted will help ease vaccine supply shortages and significantly ramp up the pace of inoculations in the U.S. Read More
GlaxoSmithKline (GSK) and Germany-based CureVac announced that they will co-develop a messenger-RNA-based COVID-19 vaccine to protect against multiple emerging variants of the SARS-CoV-2 virus. Read More
Chinese researchers have reported that two vaccines developed in China can elicit an immune response against the COVID-19 variant first identified in South Africa but at reduced levels. Read More
AstraZeneca and the University of Oxford said they are working “as rapidly as possible” to tailor their COVID-19 vaccine for significant new coronavirus mutations and believe the revamped vaccine will be ready in the fall — and that their existing vaccine has been shown to reduce transmission of disease. Read More
Peer-reviewed interim results from the Gamaleya Research Institute’s phase 3 vaccine trial showed that its Sputnik V vaccine was safe and nearly 92 percent effective against symptomatic coronavirus, encouraging results that line up with previous data released by Moscow researchers. Read More
The Pfizer/BioNTech vaccine may not protect against a key mutation found on the coronavirus variant identified in South Africa, B.1.351, new UK research suggests. Read More
The AstraZeneca/Oxford University COVID-19 vaccine offers sustained protection of 76 percent effectiveness for three months following an initial dose, Oxford researchers reported in early results from multiple trials in the UK, Brazil and South Africa. Read More